Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer

Andrea Decensi, Rosalba Torrisi, Alberto Gozza, Gianluca Severi, Gianfilippo Bertelli, Vincenzo Fontana, Floriana Pensa, Lauro Carozzo, Attilio Traverseo, Sabatino Milone, Dario Dini, Alberto Costa

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Prolonged administration of natural or synthetic retinoids has been associated with significant skeletal abnormalities, including osteoporosis. We studied the effects of the synthetic retinoid fenretinide (N-4-hydroxyphenylretinamide, or 4-HPR) administered for a mean of 40 months on bone mineral density and metabolism in 66 consecutive women with early breast cancer belonging to a secondary prevention trial. The mean (± SD) bone mineral density at the distal and ultradistal forearm were, respectively, 0.61 ± 0.08 and 0.30 ± 0.05 g/cm2 in 33 treated women and 0.62 ± 0.07 and 0.29 ± 0.07 g/cm2 in 33 control women (p = ns for both). Also, no significant difference was observed in markers of bone formation such as bone alkaline phosphatase and osteocalcin, nor in urinary bone resorption markers such as calcium, hydroxyproline, and type I bone collagen cross-linked N-telopeptide (NTx). However, a border-line higher excretion of urinary calcium and NTx was found in the 4-HPR group after adjustment for menopausal status. We conclude that prolonged administration of 4-HPR is not associated with significant alterations of bone mineral density of the forearm. However, a trend towards an increase in bone resorption markers suggests the need for further assessment at different skeletal sites.

Original languageEnglish
Pages (from-to)145-151
Number of pages7
JournalBreast Cancer Research and Treatment
Volume53
Issue number2
DOIs
Publication statusPublished - 1999

Fingerprint

Fenretinide
Bone Density
Breast Neoplasms
Retinoids
Bone Resorption
Forearm
Calcium
Bone and Bones
Needs Assessment
Hydroxyproline
Osteocalcin
Collagen Type I
Secondary Prevention
Osteogenesis
Osteoporosis
Alkaline Phosphatase

Keywords

  • Bone mineral density
  • Bone remodeling
  • Breast
  • Chemoprevention
  • Neoplasms
  • Retinoids

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer. / Decensi, Andrea; Torrisi, Rosalba; Gozza, Alberto; Severi, Gianluca; Bertelli, Gianfilippo; Fontana, Vincenzo; Pensa, Floriana; Carozzo, Lauro; Traverseo, Attilio; Milone, Sabatino; Dini, Dario; Costa, Alberto.

In: Breast Cancer Research and Treatment, Vol. 53, No. 2, 1999, p. 145-151.

Research output: Contribution to journalArticle

Decensi, A, Torrisi, R, Gozza, A, Severi, G, Bertelli, G, Fontana, V, Pensa, F, Carozzo, L, Traverseo, A, Milone, S, Dini, D & Costa, A 1999, 'Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer', Breast Cancer Research and Treatment, vol. 53, no. 2, pp. 145-151. https://doi.org/10.1023/A:1006160523497
Decensi, Andrea ; Torrisi, Rosalba ; Gozza, Alberto ; Severi, Gianluca ; Bertelli, Gianfilippo ; Fontana, Vincenzo ; Pensa, Floriana ; Carozzo, Lauro ; Traverseo, Attilio ; Milone, Sabatino ; Dini, Dario ; Costa, Alberto. / Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer. In: Breast Cancer Research and Treatment. 1999 ; Vol. 53, No. 2. pp. 145-151.
@article{5f465bffc56a498bb94cda754e022a91,
title = "Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer",
abstract = "Prolonged administration of natural or synthetic retinoids has been associated with significant skeletal abnormalities, including osteoporosis. We studied the effects of the synthetic retinoid fenretinide (N-4-hydroxyphenylretinamide, or 4-HPR) administered for a mean of 40 months on bone mineral density and metabolism in 66 consecutive women with early breast cancer belonging to a secondary prevention trial. The mean (± SD) bone mineral density at the distal and ultradistal forearm were, respectively, 0.61 ± 0.08 and 0.30 ± 0.05 g/cm2 in 33 treated women and 0.62 ± 0.07 and 0.29 ± 0.07 g/cm2 in 33 control women (p = ns for both). Also, no significant difference was observed in markers of bone formation such as bone alkaline phosphatase and osteocalcin, nor in urinary bone resorption markers such as calcium, hydroxyproline, and type I bone collagen cross-linked N-telopeptide (NTx). However, a border-line higher excretion of urinary calcium and NTx was found in the 4-HPR group after adjustment for menopausal status. We conclude that prolonged administration of 4-HPR is not associated with significant alterations of bone mineral density of the forearm. However, a trend towards an increase in bone resorption markers suggests the need for further assessment at different skeletal sites.",
keywords = "Bone mineral density, Bone remodeling, Breast, Chemoprevention, Neoplasms, Retinoids",
author = "Andrea Decensi and Rosalba Torrisi and Alberto Gozza and Gianluca Severi and Gianfilippo Bertelli and Vincenzo Fontana and Floriana Pensa and Lauro Carozzo and Attilio Traverseo and Sabatino Milone and Dario Dini and Alberto Costa",
year = "1999",
doi = "10.1023/A:1006160523497",
language = "English",
volume = "53",
pages = "145--151",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer

AU - Decensi, Andrea

AU - Torrisi, Rosalba

AU - Gozza, Alberto

AU - Severi, Gianluca

AU - Bertelli, Gianfilippo

AU - Fontana, Vincenzo

AU - Pensa, Floriana

AU - Carozzo, Lauro

AU - Traverseo, Attilio

AU - Milone, Sabatino

AU - Dini, Dario

AU - Costa, Alberto

PY - 1999

Y1 - 1999

N2 - Prolonged administration of natural or synthetic retinoids has been associated with significant skeletal abnormalities, including osteoporosis. We studied the effects of the synthetic retinoid fenretinide (N-4-hydroxyphenylretinamide, or 4-HPR) administered for a mean of 40 months on bone mineral density and metabolism in 66 consecutive women with early breast cancer belonging to a secondary prevention trial. The mean (± SD) bone mineral density at the distal and ultradistal forearm were, respectively, 0.61 ± 0.08 and 0.30 ± 0.05 g/cm2 in 33 treated women and 0.62 ± 0.07 and 0.29 ± 0.07 g/cm2 in 33 control women (p = ns for both). Also, no significant difference was observed in markers of bone formation such as bone alkaline phosphatase and osteocalcin, nor in urinary bone resorption markers such as calcium, hydroxyproline, and type I bone collagen cross-linked N-telopeptide (NTx). However, a border-line higher excretion of urinary calcium and NTx was found in the 4-HPR group after adjustment for menopausal status. We conclude that prolonged administration of 4-HPR is not associated with significant alterations of bone mineral density of the forearm. However, a trend towards an increase in bone resorption markers suggests the need for further assessment at different skeletal sites.

AB - Prolonged administration of natural or synthetic retinoids has been associated with significant skeletal abnormalities, including osteoporosis. We studied the effects of the synthetic retinoid fenretinide (N-4-hydroxyphenylretinamide, or 4-HPR) administered for a mean of 40 months on bone mineral density and metabolism in 66 consecutive women with early breast cancer belonging to a secondary prevention trial. The mean (± SD) bone mineral density at the distal and ultradistal forearm were, respectively, 0.61 ± 0.08 and 0.30 ± 0.05 g/cm2 in 33 treated women and 0.62 ± 0.07 and 0.29 ± 0.07 g/cm2 in 33 control women (p = ns for both). Also, no significant difference was observed in markers of bone formation such as bone alkaline phosphatase and osteocalcin, nor in urinary bone resorption markers such as calcium, hydroxyproline, and type I bone collagen cross-linked N-telopeptide (NTx). However, a border-line higher excretion of urinary calcium and NTx was found in the 4-HPR group after adjustment for menopausal status. We conclude that prolonged administration of 4-HPR is not associated with significant alterations of bone mineral density of the forearm. However, a trend towards an increase in bone resorption markers suggests the need for further assessment at different skeletal sites.

KW - Bone mineral density

KW - Bone remodeling

KW - Breast

KW - Chemoprevention

KW - Neoplasms

KW - Retinoids

UR - http://www.scopus.com/inward/record.url?scp=0032950990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032950990&partnerID=8YFLogxK

U2 - 10.1023/A:1006160523497

DO - 10.1023/A:1006160523497

M3 - Article

C2 - 10326791

AN - SCOPUS:0032950990

VL - 53

SP - 145

EP - 151

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -